The DOI matches its Crossref record; 13 of the 14 references it cites were found in a registry or an index.
Lack of apolipoprotein E dramatically reduces amyloid β-peptide deposition
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“ApoE is strongly associated with the amount of fibrillar amyloid that deposits into plaques (28).”
From Human ApoE isoforms differentially regulate brain amyloid-β peptide clearance (2011) · cites this paper as [28]
In the citing paper
“In addition to isoform status, it appears that the amount of apoE also plays a role in determining the extent of Aβ accumulation in the brain.”
From Haploinsufficiency of Human APOE Reduces Amyloid Deposition in a Mouse Model of Amyloid-β Amyloidosis (2011) · cites this paper as Bales et al., 1997
In the citing paper
“Initial studies clearly indicated that the deletion of the endogenous murine Apoe gene causes a dramatic decrease in fibrillar and total Aβ deposition in APP transgenic mouse models (Bales et al., 1997).”
From Haploinsufficiency of Human APOE Reduces Amyloid Deposition in a Mouse Model of Amyloid-β Amyloidosis (2011) · cites this paper as Bales et al., 1997
In the citing paper
“Previous studies demonstrated that the lack of apoE led to a dramatic decrease of amyloid deposition in APP transgenic mouse models (Bales et al., 1997; Holtzman et al., 2000b).”
From Overexpression of Low-Density Lipoprotein Receptor in the Brain Markedly Inhibits Amyloid Deposition and Increases Extracellular Aβ Clearance (2009) · cites this paper as Bales et al., 1997
In the citing paper
“Previous studies demonstrated that the absence of apoE leads to a dramatic decrease in the levels of fibrillar Aβ deposits in APP transgenic mouse models (Bales et al., 1999; Bales et al., 1997; Holtzman et al., 2000a; Holtzman et al., 2000b).”
From Overexpression of Low-Density Lipoprotein Receptor in the Brain Markedly Inhibits Amyloid Deposition and Increases Extracellular Aβ Clearance (2009) · cites this paper as Bales et al., 1997
In the citing paper
“Later, in vivo studies demonstrated that the lack of apoE led to a dramatic reduction of fibrillar Aβ deposition in APP transgenic mouse models (Bales et al., 1999; Bales et al., 1997; Holtzman et al., 2000a; Holtzman et al., 2000b).”
From Overexpression of Low-Density Lipoprotein Receptor in the Brain Markedly Inhibits Amyloid Deposition and Increases Extracellular Aβ Clearance (2009) · cites this paper as Bales et al., 1997
In the citing paper
“Reducing ApoE in mouse models of amyloidosis greatly reduces plaque formation (7, 8, 33, 34).”
From The E3 ubiquitin ligase Idol controls brain LDL receptor expression, ApoE clearance, and Aβ amyloidosis (2015) · cites this paper as [33]
In the citing paper
“Both genetic deletion and pharmacological reduction of APOE reduced Aβ deposition in mouse models of AD. 3 , 4 , 5 , 6 , 7 , 8 , 9”
From Deletion of neuronal Idol ameliorates Alzheimer's disease–related pathologies via APOE receptors (2025) · cites this paper as [3]
In the citing paper
“Notably, deletion of Apoe reduces amyloid deposition in transgenic mouse models of AD. 3 , 4”
From Deletion of neuronal Idol ameliorates Alzheimer's disease–related pathologies via APOE receptors (2025) · cites this paper as [3]
In the citing paper
“Our findings remain consistent with the effects of apoE knock-out noted in several AD Tg mouse models, where lack of apoE was associated with absence of fibrillar Aβ deposits and prevented neurodegeneration [13,29,31,32].”
From Blocking the apoE/Aβ interaction ameliorates Aβ-related pathology in APOE ε2 and ε4 targeted replacement Alzheimer model mice (2014) · cites this paper as [31]
In the citing paper
“Independent of apoE isoform, the amount of apoE in the brain appears to be critical for determining the extent of amyloid deposition [25,26].”
From Measurement of apolipoprotein E and amyloid β clearance rates in the mouse brain using bolus stable isotope labeling (2012) · cites this paper as [25]
In the citing paper
“ApoE gene deletion in APP transgenic mice leads to dramatically decreased amyloid plaques without affecting Aβ production (Bales et al., 1997).”
From Apolipoprotein E in Synaptic Plasticity and Alzheimer’s Disease: Potential Cellular and Molecular Mechanisms (2014) · cites this paper as Bales et al., 1997
In the citing paper
“The pivotal role of ApoE in brain Ab accumulation was confirmed by showing a marked reduction in Ab plaque and CAA deposits associated with the Apoe gene knockout (KO) in AD transgenic (Tg) mice.14”
From Blocking the Interaction between Apolipoprotein E and Aβ Reduces Intraneuronal Accumulation of Aβ and Inhibits Synaptic Degeneration (2013) · cites this paper as [14]
In the citing paper
“Similar effects of the ApoE KO were previously reported in APP V717F and APP SW lines, representing more latent models of Ab pathology in which thioflavin-S detects the first plaques around the age of 1 year.14,55”
From Blocking the Interaction between Apolipoprotein E and Aβ Reduces Intraneuronal Accumulation of Aβ and Inhibits Synaptic Degeneration (2013) · cites this paper as [14]
In the citing paper
“Reducing ApoE levels is generally protective in AD models1,4–6.”
From Decreased lipidated ApoE‐receptor interactions confer protection against pathogenicity of ApoE and its lipid cargoes in lysosomes (2025) · cites this paper as [4]
In the citing paper
“Previous studies showed that apoE is co-deposited in senile plaques and plays a crucial role in fibrillar plaque formation (23, 24).”
From APOE3 -Jacksonville (V236E) variant reduces self-aggregation and risk of dementia (2021) · cites this paper as [23]
In the citing paper
“In amyloid precursor proteineexpressing transgenic mice, deletion of mouse apoE gene inhibits development of fibrillar amyloid plaques [80,81].”
From Plasma levels of apolipoprotein E, APOE genotype and risk of dementia and ischemic heart disease: A review (2016) · cites this paper as [80]
In the citing paper
“ApoE strongly regulates brain amyloid-β (Aβ) deposition in a dose- and isoform-dependent manner (E4>E3>E2) (Bales et al., 1997; Holtzman et al., 2000; Schmechel et al., 1993).”
From Overexpressing low‐density lipoprotein receptor reduces tau‐associated neurodegeneration in relation to apoE‐linked mechanisms (2021) · cites this paper as Bales et al., 1997
In the citing paper
“APP transgenic mice lacking endogenous mouse apoE display a significant decrease of amyloid pathology”
From ApoE4 reduction: An emerging and promising therapeutic strategy for Alzheimer's disease (2022) · cites this paper as Bales et al 1997
In the citing paper
“apoE-deficient APP transgenic mice display virtually no fibrillar Aβ deposits nor neuritic degeneration”
From ApoE4 reduction: An emerging and promising therapeutic strategy for Alzheimer's disease (2022) · cites this paper as Bales et al 1997
In the citing paper
“Initial studies using the PDAPP and Tg2576 APP transgenic mouse models that develop Aβ deposition demonstrated that the lack of murine apoE resulted in a significant decrease in Aβ deposition, along with an almost complete lack of true amyloid plaques and neuritic dystrophy (Bales et al., 1997; Holtzman et al., 2000; Holtzman et al., 1999).”
From The role of apolipoprotein E in Alzheimer's disease (2009) · cites this paper as Bales et al., 1997
In the citing paper
“Data from transgenic mouse models produced more conflicting results with impaired plaque deposition seen in mice lacking murine APOE (Bales et al., 1997; Holtzman et al., 2000), but also in animals overexpressing the human APOE3 or APOE4 isoforms (Holtzman et al., 1999).”
From The Pro-Neurotrophin Receptor Sortilin Is a Major Neuronal Apolipoprotein E Receptor for Catabolism of Amyloid-β Peptide in the Brain (2013) · cites this paper as Bales et al., 1997
In the citing paper
“Murine Apoe deletion reduced Aβ deposition in various transgenic APP mouse models (Bales, Verina et al. 1997, Bales, Verina et al. 1999, Holtzman, Fagan et al. 2000, Irizarry, Cheung et al. 2000, Ulrich, Ulland et al. 2018)”
From SORLA up-regulation suppresses pathological effects in aged tauopathy mouse brain (2026) · cites this paper as Bales, Verina et al. 1997
In the citing paper
“ApoE has a major impact on the generation of amyloid deposits in the AD mouse brain and deletion of ApoE in most AD mouse models significantly inhibits amyloid plaque formation [6], [7], [8].”
From Lack of LDL receptor enhances amyloid deposition and decreases glial response in an Alzheimer's disease mouse model (2011) · cites this paper as [8]
In the citing paper
“APP transgenic mice deficient for ApoE show a dramatic decrease in fibrillary amyloid deposits [5], [6], [7], [8], [9].”
From Lack of LDL receptor enhances amyloid deposition and decreases glial response in an Alzheimer's disease mouse model (2011) · cites this paper as [8]
In the citing paper
“Total body apoE knockout as well as astrocyte specific ApoE knockout results in markedly decreased fibrillar amyloid deposition and in less compact Aβ plaques as well as decreasing neuronal loss and reactive gliosis in a tauopathy model [96, 99, 100].”
From ApoE lipoproteins in the central nervous system under homeostasis and role in Alzheimer’s disease and related disorders (2026) · cites this paper as [100]
In the citing paper
“In addition, the strongest genetic risk factor for LOAD, apolipoprotein E, APOE, in large part appears to increase risk via influencing Aβ seeding and clearance”
From Alzheimer Disease: An Update on Pathobiology and Treatment Strategies (2019) · cites this paper as Bales et al., 1997
In the citing paper
“To date, substantial evidence has demonstrated ApoE affects amyloid-β deposition in a dosage and isoform-specific fashion (ApoE4>ApoE3>ApoE2)96–100”
From Interplay between innate immunity and Alzheimer disease: APOE and TREM2 in the spotlight (2018) · cites this paper as [96]
In the citing paper
“Transgenic mouse studies confirmed that ApoE was necessary for the formation of fibrillar amyloid plaques and CAA [4, 5, 41, 61], however they also identified important differences between mouse and human ApoE.”
From Alzheimer's disease: experimental models and reality (2017) · cites this paper as [5]
Citations
Cites
Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein
Games, D., Adams, D., Alessandrini, R., Barbour, R., Borthelette, P., Blackwell, C., Carr, T., Clemens, J., Donaldson, T., Gillespie, F., et al. (1995) · Nature · doi:10.1038/373523a0 · Cited by 2,516
Self-citationSpontaneous Hypercholesterolemia and Arterial Lesions in Mice Lacking Apolipoprotein E
Zhang, S. H., Reddick, R. L., Piedrahita, J. A., & Maeda, N. (1992) · Science · doi:10.1126/science.1411543 · Cited by 2,237
Apolipoprotein E polymorphism and Alzheimer's disease
Poirier, J., Bertrand, P., Poirier, J., Kogan, S., Gauthier, S., Poirier, J., Gauthier, S., Davignon, J., Bouthillier, D., & Davignon, J. (1993) · The Lancet · doi:10.1016/0140-6736(93)91705-q · Cited by 1,108
Ma, J., Yee, A., Brewer, H. B., Das, S., & Potter, H. (1994) · Nature · doi:10.1038/372092a0 · Cited by 871
Normal and Abnormal Biology of the Beta-Amyloid Precursor Protein
Selkoe, D. J. (1994) · Annual Review of Neuroscience · doi:10.1146/annurev.ne.17.030194.002421 · Cited by 834
Reduction of β‐amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease
Motter, R., Vigo‐Pelfrey, C., Kholodenko, D., Barbour, R., Johnson‐Wood, K., Galasko, D., Chang, L., Miller, B., Clark, C., Green, R., et al. (1995) · Annals of Neurology · doi:10.1002/ana.410380413 · Cited by 701
Apolipoprotein E and Alzheimer disease.
Strittmatter, W. J., & Roses, A. D. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.11.4725 · Cited by 701
(1997) · doi:10.1073/pnas.94.4.1550 · Cited by 535
Human apolipoprotein E: the Alzheimer's disease connection
Weisgraber, K. H., & Mahley, R. W. (1996) · The FASEB Journal · doi:10.1096/fasebj.10.13.8940294 · Cited by 333
Hyman, B. T., West, H. L., Rebeck, G. W., Buldyrev, S. V., Mantegna, R. N., Ukleja, M., Havlin, S., & Stanley, H. E. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.8.3586 · Cited by 212
Research works printed but not linked: 2
- Kim, K.S. et al. Neurosci. Res. Comm. 51, 113–122 (1990).
- Brown, B.M. & Hettmansperger, T.P. J. Am. Stat. Assoc. 91, 1668–1675 (1996).
Cited by
Sorted by citations
Items 301–400 of 829
Molecular genetics of Alzheimerʼs disease: the role of β-amyloid and the presenilins
Tandon, A., Rogaeva, E. A., MULLAN, M. J., & George‐Hyslop, P. S. (2000) · Current Opinion in Neurology · doi:10.1097/00019052-200008000-00003 · Cited by 81
Heparan sulfate as a therapeutic target in amyloidogenesis: prospects and possible complications
Kisilevsky, R., Ancsin, J. B., Szarek, W. A., & Petanceska, S. S. (2007) · Amyloid · doi:10.1080/13506120601116419 · Cited by 79
Myllykangas, L., Polvikoski, T. M., Sulkava, R. O., Verkkoniemi, A., Crook, R., Tienari, P. J., Pusa, A., Niinistö, L., O’Brien, P. C., KONTULA, K. K., et al. (1999) · PubMed · Cited by 79
Amyloid excess in Alzheimer's disease: What is cholesterol to be blamed for?
Ledesma, M. D., & Dotti, C. G. (2006) · FEBS Letters · doi:10.1016/j.febslet.2006.06.038 · Cited by 80
Soto, C. A. (1999) · Journal of Molecular Medicine · doi:10.1007/s001090050371 · Cited by 78
Liao, F., Zhang, T. J., Jiang, H., Lefton, K. B., Robinson, G. O., Vassar, R., Sullivan, P. M., & Holtzman, D. M. (2015) · Acta Neuropathologica Communications · doi:10.1186/s40478-015-0250-y · Cited by 77
Exosome Production Is Key to Neuronal Endosomal Pathway Integrity in Neurodegenerative Diseases
Mathews, P. M., & Levy, E. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.01347 · Cited by 81
Cholesterol-related genes in Alzheimer's disease
Wollmer, M. A. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2010.05.009 · Cited by 78
Halford, R. W., & Russell, D. W. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813349106 · Cited by 75
Apolipoprotein E modulates γ‐secretase cleavage of the amyloid precursor protein
Irizarry, M. C., Deng, A., Lleo, A., Berezovska, O., Von Arnim, C. A. F., Martin‐Rehrmann, M., Manelli, A., LaDu, M. J., Hyman, B. T., & Rebeck, G. W. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02581.x · Cited by 89
Identification and validation of novel CSF biomarkers for early stages of Alzheimer's disease
Hu, Y., Hosseini, A., Kauwe, J. S. K., Gross, J., Cairns, N. J., Goate, A., Fagan, A. M., Townsend, R. R., & Holtzman, D. M. (2007) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.200600999 · Cited by 75
Intracellular A-Beta Amyloid, A Sign for Worse Things to Come?
Echeverría, V., & Cuello, A. C. (2002) · Molecular Neurobiology · doi:10.1385/mn:26:2-3:299 · Cited by 81
Vasilevko, V., Passos, G. F., Quiring, D., Head, E., Kim, R. C., Fisher, M., & Cribbs, D. H. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2010.05786.x · Cited by 74
Amelioration of the Alzheimer's Disease Phenotype by Absence of 12/15-Lipoxygenase
Yang, H., Zhuo, J., Chu, J., Chinnici, C. M., & Praticò, D. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.04.010 · Cited by 75
Johnson, E. C. B., Ho, K., Yu, G.-Q., Das, M., Sanchez, P. E., Djukic, B., Lopez, I., Yu, X., Gill, M., Zhang, W., et al. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00393-5 · Cited by 73
Yue, Q., & Hoi, M. P. M. (2023) · Neural Regeneration Research · doi:10.4103/1673-5374.367832 · Cited by 78
Savas, J. N., Wang, Y.-Z., DeNardo, L. A., Martinez-Bartolome, S., McClatchy, D. B., Hark, T. J., Shanks, N. F., Cozzolino, K. A., Lavallée-Adam, M., Smukowski, S. N., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.11.009 · Cited by 66
Katsouri, L., & Georgopoulos, S. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021880 · Cited by 72
Gadhave, K., Kumar, D., Uversky, V. N., & Giri, R. (2020) · Medicinal Research Reviews · doi:10.1002/med.21719 · Cited by 71
Membrane dynamics, cholesterol homeostasis, and Alzheimer's disease
Chauhan, N. B. (2003) · Journal of Lipid Research · doi:10.1194/jlr.r300010-jlr200 · Cited by 64
Adav, S. S., & Sze, S. K. (2016) · Molecular Brain · doi:10.1186/s13041-016-0272-9 · Cited by 75
Buxbaum, J. D., Geoghagen, N. S. M., & Friedhoff, L. T. (2001) · Journal of Alzheimer s Disease · doi:10.3233/jad-2001-3207 · Cited by 69
Genetics of Alzheimer’s Disease in Caribbean Hispanic and African American Populations
Reitz, C., & Mayeux, R. P. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.06.003 · Cited by 69
Inhibition of Amyloidosis Using Low-Molecular-Weight Heparins
Zhu, H., Yu, J., & Kindy, M. S. (2001) · Molecular Medicine · doi:10.1007/bf03401857 · Cited by 71
Nishitsuji, K., Hosono, T., Uchimura, K., & Michikawa, M. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.172106 · Cited by 65
Mechanisms of Neurodegenerative Disorders
Wolozin, B. L., & Behl, C. (2000) · Archives of Neurology · doi:10.1001/archneur.57.6.793 · Cited by 70
Ito, S., Ohtsuki, S., Kamiie, J., Nezu, Y., & Terasaki, T. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.04938.x · Cited by 85
Lewandowski, C. T., Maldonado Weng, J., & LaDu, M. J. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104811 · Cited by 72
Hamley, I. W. (2007) · Angewandte Chemie · doi:10.1002/ange.200700861 · Cited by 69
β-Site APP Cleaving Enzyme mRNA Expression in APP Transgenic Mice
Irizarry, M. C., Locascio, J. J., & Hyman, B. T. (2001) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)63955-7 · Cited by 69
The role of apolipoprotein E in lipid metabolism in the central nervous system
Han, X. (2004) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-004-4009-z · Cited by 69
Clinical and Neuropathological Correlates of Apolipoprotein E Genotype in Dementia with Lewy Bodies
Singleton, A., Wharton, A., O’Brien, K. K., Walker, M. P., McKeith, I. G., Ballard, C. G., O'Brien, J. T., Perry, R. H., Ince, P. G., Edwardson, J. A., et al. (2002) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000066022 · Cited by 69
Isolation and Characterization of Apolipoproteins from Murine Microglia
Xu, Q., Li, Y., Cyras, C., Sanan, D. A., & Cordell, B. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m002796200 · Cited by 69
Kuo, Y., Crawford, F., MULLAN, M. J., Kokjohn, T. A., Emmerling, M. R., Weller, R. O., & Roher, A. E. (2000) · Molecular Medicine · doi:10.1007/bf03401785 · Cited by 68
Human apolipoprotein E4 accelerates β‐amyloid deposition in APPsw transgenic mouse brain
Carter, D. B., Dunn, E., McKinley, D. D., Stratman, N. C., Boyle, T. P., Kuiper, S. L., Oostveen, J. A., Weaver, R. J., Boller, J. A., & Gurney, M. E. (2001) · Annals of Neurology · doi:10.1002/ana.1134 · Cited by 70
Protein aggregates and dementia: is there a common toxicity?
Lovestone, S. (2002) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.72.2.152 · Cited by 69
Modulation of β-Amyloid Fibril Formation in Alzheimer’s Disease by Microglia and Infection
Brown, M. R., Radford, S. E., & Hewitt, E. W. (2020) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2020.609073 · Cited by 67
Macrophage-Mediated Degradation of β-Amyloid via an Apolipoprotein E Isoform-Dependent Mechanism
Zhao, L., Lin, S., Bales, K. R., Gelfanova, V., Koger, D., DeLong, C. A., Hale, J. E., Liu, F., Hunter, J. M., & Paul, S. M. (2009) · Journal of Neuroscience · doi:10.1523/jneurosci.5302-08.2009 · Cited by 70
Self-citationLawlor, P. A., Bland, R. J., Das, P., Price, R. W., Holloway, V., Smithson, L., Dicker, B. L., During, M. J., Young, D., & Golde, T. E. (2007) · Molecular Neurodegeneration · doi:10.1186/1750-1326-2-11 · Cited by 67
Han, S.-H., Park, J.-C., & Mook-Jung, I. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.12.004 · Cited by 67
Alzheimer’s Disease Risk Genes and Lipid Regulators
Gaamouch, F. E., Jing, P., Xia, J., & Cai, D. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160169 · Cited by 67
Progress toward valid transgenic mouse models for Alzheimer’s disease
Guénette, S. Y., & Tanzi, R. E. (1999) · Neurobiology of Aging · doi:10.1016/s0197-4580(99)00042-1 · Cited by 67
The generation and function of soluble apoE receptors in the CNS
Rebeck, G. W., LaDu, M. J., Estus, S., Bu, G., & Weeber, E. J. (2006) · Molecular Neurodegeneration · doi:10.1186/1750-1326-1-15 · Cited by 66
Xia, Y., Wang, Z.-H., Zhang, J., Liu, X., Yu, S. P., Ye, K. X., Wang, J., Ye, K., & Wang, X. (2020) · Molecular Psychiatry · doi:10.1038/s41380-020-00956-4 · Cited by 66
Role of Apolipoprotein E in β-Amyloidogenesis
Hori, Y., Hashimoto, T., Nomoto, H., Hyman, B. T., & Iwatsubo, T. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.622209 · Cited by 69
Maarouf, C. L., Kokjohn, T. A., Whiteside, C. M., Macias, M. P., Kalback, W. M., Sabbagh, M. N., Beach, T. G., Vassar, R. J., & Roher, A. E. (2013) · Biochemistry Insights · doi:10.4137/bci.s13025 · Cited by 64
Modulation of Aβ Deposition in APP Transgenic Mice by an Apolipoprotein E Null Background
IRIZARRY, M. C., REBECK, G. W., CHEUNG, B., BALES, K., PAUL, S. M., HOLZMAN, D., & HYMAN, B. T. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb06919.x · Cited by 66
Self-citationHuang, F., Buttini, M., Wyss-Coray, T., McConlogue, L., Kodama, T., Pitas, R. E., & Mucke, L. (1999) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65489-2 · Cited by 49
The Interaction of Amyloid-β with ApoE
Carter, D. B. (2005) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/0-387-23226-5_13 · Cited by 68
Burgess, B. L., Parkinson, P. F., Racke, M. M., Hirsch‐Reinshagen, V., Fan, J., Wong, C. A., Stukas, S. K., Théroux, L., Chan, J. Y., Donkin, J. J., et al. (2008) · Journal of Lipid Research · doi:10.1194/jlr.m700481-jlr200 · Cited by 66
APOE-ε4 and APOE −491A polymorphisms in individuals with subjective memory loss
Laws, S. M., Clarnette, R., Taddei, K., Martins, G., Paton, A., Hallmayer, J. F., Almeida, O. P., Groth, D., Gandy, S., Förstl, H., et al. (2002) · Molecular Psychiatry · doi:10.1038/sj.mp.4001083 · Cited by 64
The relation of proteoglycans, serum amyloid P and Apo E to amyloidosis current status, 2000
Kisilevsky, R. (2000) · Amyloid · doi:10.3109/13506120009146820 · Cited by 64
Holtzman, D. M., Bales, K. R., Paul, S. M., & Demattos, R. B. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00158-8 · Cited by 64
Self-citationCholesterol modulation as an emerging strategy for the treatment of Alzheimer's disease
Golde, T. E., & Eckman, C. B. (2001) · Drug Discovery Today · doi:10.1016/s1359-6446(01)01965-1 · Cited by 64
Kay, A. D., Petzold, A., Kerr, M., Keir, G., Thompson, E. J., & Nicoll, J. A. R. (2003) · Journal of Neurotrauma · doi:10.1089/089771503770195795 · Cited by 64
Mannix, R. C., Zhang, J., Park, J., Zhang, X., Bilal, K., Walker, K., Tanzi, R. E., Tesco, G., & Whalen, M. J. (2011) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2010.99 · Cited by 62
Amyloid and lipids in the pathology of Alzheimer disease
Roher, A. E., Kuo, Y., Kokjohn, K., Emmerling, M. R., & Gracon, S. I. (1999) · Amyloid · doi:10.3109/13506129909007315 · Cited by 63
Wang, M., Tang, G., Zhou, C., Guo, H., Hu, Z., Hu, Q., & Li, G. (2023) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2023.110387 · Cited by 62
Hirsch-Reinshagen, V., & Wellington, C. L. (2007) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32813aeabf · Cited by 61
ApoE4 reduction: An emerging and promising therapeutic strategy for Alzheimer's disease
Li, Y., Macyczko, J. R., Liu, C.-C., & Bu, G. (2022) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2022.03.011 · Cited by 61
Mortalin is regulated by APOE in hippocampus of AD patients and by human APOE in TR mice
Osorio, C., Sullivan, P. M., Dong, H., Mace, B. E., Ervin, J. F., Strittmatter, W. J., & Álzate, Ó. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.08.011 · Cited by 62
Kanai, M., Shizuka, M., Urakami, K., Matsubara, E., Harigaya, Y., Okamoto, K., & Shoji, M. (1999) · Neuroscience Letters · doi:10.1016/s0304-3940(99)00323-7 · Cited by 61
Effects of APOE4 allelic dosage on lipidomic signatures in the entorhinal cortex of aged mice
Miranda, A. M., Ashok, A., Chan, R. B., Zhou, B., Xu, Y., McIntire, L. B., Area-Gomez, E., Di Paolo, G., Duff, K. E., Oliveira, T. G., et al. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-01881-6 · Cited by 60
Ibuprofen, inflammation and Alzheimer disease
Wyss‐Coray, T., & Mucke, L. (2000) · Nature Medicine · doi:10.1038/79661 · Cited by 59
The association between APOE and dementia does not seem to be mediated by vascular factors
Prince, M. J., Lovestone, S., Cervilla, J. A., Joels, S., Powell, J. F., Russ, C., & MANN, A. H. (2000) · Neurology · doi:10.1212/wnl.54.2.397 · Cited by 60
Genetics of Alzheimer’s disease: From pathogenesis to clinical usage
Shao, W., Peng, D., & Wang, X. (2017) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2017.06.074 · Cited by 64
Chapter 9 Oxidative Stress in Malignant Progression
Trougakos, I. P., & Gonos, E. S. (2009) · Advances in cancer research · doi:10.1016/s0065-230x(09)04009-3 · Cited by 60
Reitz, C., & Mayeux, R. P. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-1255 · Cited by 60
Thal, D. R., Larionov, S., Abramowski, D., Wiederhold, K., Dooren, T. V., Yamaguchi, H., Haass, C., LEUVEN, F. V., Staufenbiel, M., & Capetillo‐Zarate, E. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.05.029 · Cited by 59
Brendza, R. P., O'Brien, C., Simmons, K. A., McKeel, D. W., Bales, K. R., Paul, S. M., Olney, J. W., Sanes, J. R., & Holtzman, D. M. (2003) · The Journal of Comparative Neurology · doi:10.1002/cne.10536 · Cited by 59
Self-citationMemories Are Made of This: Recent Advances in Understanding Cognitive Impairments and Dementia
Banks, W. A., & Morley, J. E. (2003) · The Journals of Gerontology Series A · doi:10.1093/gerona/58.4.m314 · Cited by 57
Effect of APOE genotype and promoter polymorphism on risk of Alzheimer’s disease
Wang, J. C., Kwon, J. M., Shah, P., Morris, J. C., & Goate, A. (2000) · Neurology · doi:10.1212/wnl.55.11.1644 · Cited by 49
Cellular cofactors potentiating induction of stress and cytotoxicity by amyloid β-peptide
Yan, S. D., Roher, A. E., Chaney, M., Zloković, B. V., Schmidt, A. M., & Stern, D. M. (2000) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/s0925-4439(00)00041-7 · Cited by 58
Pankiewicz, J. E., Guridi, M., Kim, J., Asuni, A. A., Sanchez, S., Sullivan, P. M., Holtzman, D. M., & Sadowski, M. J. (2014) · Acta Neuropathologica Communications · doi:10.1186/s40478-014-0075-0 · Cited by 57
Huttunen, H. J., Havas, D., Peach, C., Barren, C., Duller, S., Xia, W., Frosch, M. P., Hutter-Paier, B., Windisch, M., & Kovacs, D. M. (2010) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3181e77ed9 · Cited by 54
Liu, S., Park, S.-A., Allington, G., Prelli, F., Sun, Y., Martá-Ariza, M., Scholtzova, H., Biswas, G. K., Brown, B., Verghese, P. B., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-08604-8 · Cited by 58
Kisilevsky, R., Szarek, W. A., Ancsin, J. B., Elimova, E. C., Marone, S., Bhat, S., & Berkin, A. (2004) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)63771-6 · Cited by 57
The link between cholesterol and Alzheimer's disease
Sjögren, M. J. C., & Blennow, K. (2005) · The World Journal of Biological Psychiatry · doi:10.1080/15622970510029795 · Cited by 60
Genetics of Early-Onset Alzheimer Dementia
Rademakers, R., Cruts, M., & Broeckhoven, C. V. (2003) · The Scientific World JOURNAL · doi:10.1100/tsw.2003.39 · Cited by 58
Area-Gomez, E., Larrea, D., Pera, M., Agrawal, R. R., Guilfoyle, D. N., Pirhaji, L., Shannon, K., Arain, H. A., Ashok, A., Chen, Q., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-61142-8 · Cited by 55
Functional analyses of major cancer-related signaling pathways in Alzheimer's disease etiology
Guo, J., Cheng, J., North, B. J., & Wei, W. (2017) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2017.07.001 · Cited by 55
Verbeek, M. M., Nostrand, W. E. V., Otte‐Höller, I., Wesseling, P., & de Waal, R. M. W. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb06368.x · Cited by 57
Molecular pathogenesis of sporadic and familial forms of Alzheimer's disease
Ray, W. J., Ashall, F., & Goate, A. (1998) · Molecular Medicine Today · doi:10.1016/s1357-4310(98)01229-5 · Cited by 55
Emilien, G., Maloteaux, J., Beyreuther, K. T., & Masters, C. L. (2000) · Archives of Neurology · doi:10.1001/archneur.57.2.176 · Cited by 55
Fagan, A. M., Christopher, E., Taylor, J. W., Parsadanian, M., Spinner, M., Watson, M., Fryer, J. D., Wahrle, S., Bales, K. R., Paul, S. M., et al. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63399-8 · Cited by 54
Self-citationCoxibs and Alzheimer's disease: Should they stay or should they go?
Firuzi, O., & Praticò, D. (2006) · Annals of Neurology · doi:10.1002/ana.20774 · Cited by 54
Lambert, J., Coyle, N., & Lendon, C. (2004) · Journal of Medical Genetics · doi:10.1136/jmg.2003.005033 · Cited by 51
Immunological and Anti-Chaperone Therapeutic Approaches for Alzheimer Disease
Wısnıewskı, T., & Frangione, B. (2006) · Brain Pathology · doi:10.1111/j.1750-3639.2005.tb00102.x · Cited by 54
Hull, R. L., Zraika, S., Udayasankar, J., Kisilevsky, R., Szarek, W. A., Wight, T. N., & Kahn, S. E. (2007) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00208.2007 · Cited by 53
Role of Trisomy 21 Mosaicism in Sporadic and Familial Alzheimer's Disease
Potter, H., Granic, A., & Caneus, J. (2015) · Current Alzheimer Research · doi:10.2174/156720501301151207100616 · Cited by 54
Chernick, D., Ortiz‐Valle, S., Jeong, A., Swaminathan, S. K., Kandimalla, K. K., Rebeck, G. W., & Li, L. (2018) · Journal of Neurochemistry · doi:10.1111/jnc.14554 · Cited by 51
Brain lipid metabolism, apolipoprotein E and the pathophysiology of Alzheimer's disease
Bales, K. R. (2010) · Neuropharmacology · doi:10.1016/j.neuropharm.2010.01.005 · Cited by 58
Self-citationMouse Models of Alzheimer's Disease: A Quest for Plaques
Richardson, J. A., & Burns, D. K. (2002) · ILAR Journal · doi:10.1093/ilar.43.2.89 · Cited by 53
Do statins slow down Alzheimer's disease? A review
Caballero, J., & Nahata, M. (2004) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2004.00560.x · Cited by 53
Introducing Human APOE into A β Transgenic Mouse Models
Tai, L. M., Youmans, K. L., Jungbauer, L., Yu, C., & LaDu, M. J. (2011) · International Journal of Alzheimer’s Disease · doi:10.4061/2011/810981 · Cited by 52
Lipidomics of Alzheimer’s Disease
Touboul, D., & Gaudin, M. (2014) · Bioanalysis · doi:10.4155/bio.13.346 · Cited by 52
Decreased Cerebrospinal Fluid Apolipoprotein E After Subarachnoid Hemorrhage
Kay, A., Petzold, A., Kerr, M., Keir, G., Thompson, E. J., & Nicoll, J. A. R. (2003) · Stroke · doi:10.1161/01.str.0000057579.25430.16 · Cited by 69
Lipoprotein receptors in Alzheimer's disease
Andersen, O. M., & Willnow, T. E. (2006) · Trends in Neurosciences · doi:10.1016/j.tins.2006.09.002 · Cited by 41
Laws, S. M., Hone, E., Taddei, K., Harper, C., Dean, B., McClean, C., Masters, C. L., Lautenschlager, N. T., Gandy, S., & Martins, R. N. (2002) · Molecular Psychiatry · doi:10.1038/sj.mp.4001097 · Cited by 51
Akram, A., Schmeidler, J., Katsel, P., Hof, P. R., & Haroutunian, V. (2010) · Brain Research · doi:10.1016/j.brainres.2010.01.006 · Cited by 50
Metadata
- Authors
- Bales, K. R., Verina, T., Dodel, R. C., Du, Y., Altstiel, L., Bender, M., Hyslop, P., Johnstone, E. M., Little, S. P., Cummins, D. J., Piccardo, P., Ghetti, B., & Paul, S. M.
- Affiliations
- Eli Lilly (United States) (US)
- Indiana University School of Medicine (US)
- Philipps University of Marburg (DE)
- Venue
- Nature Genetics
- Published
- 1997-11
- Volume
- 17
- Issue
- 3
- Pages
- 263-264
- ISSN
- 1061-4036 (ISSN-L)
- 1546-1718
- OpenAlex
- W1981554609
- Cited by
- 830
- References
- 14
- Citations by year
- 2026: 11 · 2025: 8 · 2024: 27 · 2023: 18 · 2022: 25 · 2021: 19 · 2020: 27 · 2019: 24 · 2018: 16 · 2017: 21 · 2016: 20 · 2015: 19 · 2014: 21 · 2013: 16 · 2012: 20
- FWCI
- 26.51
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Genetics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- apolipoprotein E, amyloid-beta, amyloid deposition, Alzheimer's disease, APOE genotype, apolipoprotein E deficiency
- MeSH terms
- Age Factors, Alzheimer Disease, Animals, Apolipoproteins E, Brain, Humans, Immunohistochemistry, Mice, Inbred C57BL, Mice, Inbred DBA, Mice, Transgenic, RNA, Messenger, Polymerase Chain Reaction, Amyloid beta-Peptides, Amyloid beta-Protein Precursor, Mice, Knockout, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
